BioSpace News Archive

BioForest

CTI BioPharma Announces Presentation of Data Supporting Pacritinib’s Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting

Results from Investigator-sponsored Phase 1/2 Study of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Demonstrate Encouraging Efficacy and Safety Profile when Combining Pacritinib 100 mg BID with Standard Immunosuppressive Therapy

December 6, 2020
·
6 min read
Drug Development

Combined Data from Multiple Phase 3 Studies of IMBRUVICA® (ibrutinib) Show Efficacy and Safety in High-Risk, Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Real-World Data Indicating Low Biomarker Testing Rates for These Patients

AbbVie, announced results from a long-term integrated analysis of two Phase 3 clinical studies and additional pooled analysis evaluating the effect of IMBRUVICA based therapies for the first-line treatment of high-risk patients with chronic lymphocytic leukemia.

December 6, 2020
·
22 min read
Drug Development

Xencor Presents Updated Data from the Phase 1 Study of Vibecotamab in Acute Myeloid Leukemia at the 2020 ASH Annual Meeting

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, announced updated data from its ongoing Phase 1 dose-escalation study of vibecotamab, a CD123 x CD3 bispecific antibody, in patients with relapsed or refractory acute myeloid leukemia.

December 6, 2020
·
6 min read
Aptose Presents Highlights from ASH and Corporate Update Event

Aptose Biosciences Inc. released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology Annual Meeting.

December 6, 2020
·
7 min read
Biotech Bay

Bayer and Atara Biotherapeutics Enter Strategic Collaboration for Mesothelin-Targeted CAR T-cell Therapies for Solid Tumors

Bayer and Atara Biotherapeutics, Inc. announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors.

December 6, 2020
·
11 min read
Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting

PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits

December 6, 2020
·
8 min read
Biotech Bay

Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition

Updated interimdata from CPI-818’sphase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas

December 6, 2020
·
10 min read
Drug Development

Arch Oncology Presents New Preclinical Data on Highly Differentiated Anti-CD47 Antibody AO-176 at ASH 2020

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, announced the presentation of new preclinical data on AO-176 at the ASH Annual Meeting 2020.

December 6, 2020
·
3 min read
Drug Development

Allogene Therapeutics Presents Preclinical Data on ALLO-316 in Acute Myeloid Leukemia at the 62nd Meeting of the American Society of Hematology

Investigational New Drug (IND) Application for ALLO-316 Cleared by U.S. Food and Drug Administration (FDA); Phase 1 Trial in RCC to Start in 2021

December 6, 2020
·
4 min read
Drug Development

BeiGene Announces Data on BRUKINSA® (Zanubrutinib) from Phase 2 Trial in Marginal Zone Lymphoma and Phase 3 Trial in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at the 62nd ASH Annual Meeting

Zanubrutinib was shown to be highly active in patients with relapsed/refractory marginal zone lymphoma in initial results from the Phase 2 MAGNOLIA trial

December 6, 2020
·
15 min read